Add BrightSurf on Google Email

Osimertinib with or without chemotherapy in advanced non–small cell lung cancer with EGFR and concurrent TP53 mutations

A randomized phase 3 study found that first-line osimertinib plus chemotherapy significantly improved median progression-free survival compared to osimertinib alone in patients with advanced non–small cell lung cancer (NSCLC) and concurrent EGFR and TP53 mutations. This study provides evidence for incorporating TP53-based molecular ris...

SourceJAMA Network·JournalJAMA·DateAug 10, 2026

Alzheimer's enzyme acts as a tumor suppressor

Researchers at Burnham Institute have discovered that gamma-secretase acts as a tumor suppressor by altering the EGFR pathway, which may limit treatment options for Alzheimer's and other diseases. The study also found that APP metabolite AICD negatively regulates transcription of the EGFR gene.

SourceSanford Burnham Prebys·JournalProceedings of the National Academy of Sciences·DateJun 7, 2007